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THYROID FUNCTION AND DYSFUNCTION
Thyroid Hormone Levels Within Reference Range
Are Associated with Heart Rate, Cardiac Structure,
and Function in Middle-Aged Men and Women
Greet L. Roef,1 Youri E. Taes,1 Jean-Marc Kaufman,1 Caroline M. Van Daele,2
Marc L. De Buyzere,3 Thierry C. Gillebert,2 and Ernst R. Rietzschel2
Background: Triiodothyronine (T3) has many effects on the heart, and marked changes in cardiac function and
structure occur in patients with (subclinical) thyroid disease. We investigated whether between-subject variation
in thyroid hormone levels within the euthyroid range is also associated with heart rate and echocardiographic
heart function and structure.
Methods: Subjects were selected from the Asklepios study (n = 2524), a population-representative random
sample of patients aged between 35 and 55 years, free from overt cardiovascular disease at baseline. Analyses were
restricted to 2078 subjects (1013 women and 1065 men), not using antihypertensive or thyroid medication nor
having antithyroperoxidase antibody levels above clinical cut-off or thyrotropin (TSH) levels outside the reference
range. All subjects were phenotyped in-depth and underwent comprehensive echocardiography, including dia-
stolic evaluation. Thyroid function parameters were determined by automated electrochemiluminescence.
Results: Heart rate was robustly positively associated with (quartiles of) free T3 (FT3) and T3, both in subjects with
TSH levels within reference (0.27–4.2 lU/L) and in narrow TSH range (0.5–2.5 lU/L; p <0.0001). FT3 and T3 were
negatively associated with left ventricular (LV) end-diastolic volume but positively associated with relative wall
thickness. Total T3 (TT3) was associated with enhanced ventricular contraction (as assessed by tissue Doppler
imaging). Free thyroxine, FT3, and TT3 were positively associated with late ventricular filling, and TT3 was
associated with early ventricular filling.
Conclusion: We have demonstrated a strong positive association between thyroid hormone levels within the
euthyroid range and heart rate, and more subtle effects on cardiac function and structure. More specifically, we
suggest a smaller LV cavity size (with increased relative wall thickness), an enhanced atrial and ventricular
contraction, and LV relaxation with higher circulating thyroid hormones. These results illustrate that variation in
thyroid hormone levels, even within the reference range, exerts effects on the heart.
Introduction
Triiodothyronine (T3) is known to exert various actionson the cardiovascular system, involving cardiac con-
tractility, electrophysiological function, and cardiac structure
(1–3). With regard to these contractile effects, it has positive
inotropic, chronotropic, and lusitropic effects, which means
that it stimulates the rate and force of systolic contraction and
the rate of diastolic relaxation (1,2).
Overt hyperthyroidism increases the resting heart rate,
carries a risk of (atrial) arrhythmias, and augments cardiac
contractility and output. When the duration of this hyper-
thyroidism is prolonged, the increased protein synthesis in
cardiac myocytes can lead to concentric cardiac hypertrophy
(1,2,4). A thyroid hormone deficit, in contrast, decreases
cardiac contractility and delays diastolic relaxation (4,5).
Moreover, structural changes such as asymmetric septal hy-
pertrophy (6), cardiomegaly (2), and pericardial effusion (7)
have been reported.
Subclinical (SC) thyroid disease has also been associated
with altered cardiac function and structure. Studies in SC
hypothyroidism have reported an impairment of both systolic
and diastolic function, as well as a slightly higher left ven-
tricular (LV) mass, although this mass was still within the
reference range (8,9). Conversely, in SC hyperthyroidism,
increases in LV systolic function have been observed (10,11).
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Whether this is also reflected in cardiac hypertrophy is still a
matter of debate (10–14). Of note, two studies in patients with
iatrogenic SC hyperthyroidism have shown diastolic LV
dysfunction, which was (at least in part) reversible after res-
toration of a euthyroid state (14,15).
The heart is one of the most thyroid hormone-responsive
tissues in the body, and is responsive to minimal but persis-
tent changes in circulating thyroid hormone levels (3,16).
Accordingly, it is plausible that variance in thyroid hormone
levels even within the euthyroid range could influence heart
rate, cardiac function, and structure. However, to our present
knowledge, only two studies covering this topic exist: one
smaller study performed in hypertensive subjects (17), and a
larger study from the Framingham cohort, where subjects
were categorized according to thyrotropin (TSH) levels but
without determination of free thyroid hormone levels (11).
The present study therefore investigated whether between-
subjects variation in thyroid hormone levels within the eu-
thyroid range affects heart rate, function, and structure in a
population of healthy middle-aged men and women, free of
overt cardiovascular disease.
Materials and Methods
Study population
The Asklepios study is an ongoing population study fo-
cused on the interplay of aging, cardiovascular hemo-
dynamics, and the emergence of cardiovascular disease. Study
design, inclusion and exclusion criteria, study components, and
baseline characteristics of the population have been described in
detail before (18). The cohort (n=2524; 50.5% women) is a
population-representative random sample of the general pop-
ulation aged between 35 and 55 years, free from overt cardio-
vascular disease at baseline. The data of the present investigation
were acquired during the first measuring round (2002–2004).
The study was approved by the medical ethical committee of
Ghent University Hospital, Belgium. All participants gave
written informed consent prior to enrollment. Data collection
and measurements have been described previously (18–22).
For subject selection in this paper, we refer to Figure 1.
Individuals receiving thyroid hormone substitution or
antithyroid drugs, having antithyroperoxidase antibodies
(TPOAbs) above clinical cut-off, taking antihypertensive
drugs, or with TSH levels outside the reference range of our
laboratory (0.27–4.2 mU/L) were excluded from the analyses,
leaving 2078 subjects (‘‘reference TSH range’’). As a sensitivity
analysis, we performed some analyses only in subjects within
a strictly euthyroid range (0.5–2.5 mU/L), leaving 1761 sub-
jects (‘‘narrow TSH range’’).
Measurements
Measurements were (after 15 minutes of rest, informed
consent, and review of questionnaire data in a temperature-
controlled environment): (i) basic clinical data, (ii) blood
sampling followed by a short rest, and (iii) and echocardio-
graphic examination. Blood pressure was recorded using bi-
lateral triplicate measurements (one-minute intervals) on a
rested, sitting subject using a validated oscillometric Omron
HEM-907 device (Omron Healthcare Co. Ltd., Kyoto, Japan).
Blood-pressure values for these six readings were averaged,
and the mean value was used throughout the study. A digital
12-lead (Schiller AT-104PC, Schiller AG, Baar, Switzerland)
FIG. 1. Flowchart for inclusion and exclusion of the study population. TSH, thyrotropin.
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electrocardiogram (ECG) was recorded and reviewed by a
physician. Heart rate was recorded eight times throughout the
examination period. The mean value of these eight measure-
ments was calculated and used for analyses throughout the
study, except for analyses on cardiac function, where heart
rate at the time of echocardiographic measurement was used.
The subjects underwent a resting echocardiographic exam-
ination (VIVID 7, GE Vingmed Ultrasound, Horten, Norway).
Analysis of the ECG-gated cineloops or images was performed
offline by a single, blinded, measurement-dedicated reader.
All variables were measured on at least three cardiac cycles;
reported measurements are averaged values. LV internal di-
mensions were measured at end diastole (LVEDD) and end
systole (LVESD). Wall thickness (interventricular septal dia-
meter [IVSD] and posterior wall thickness [PW]) were mea-
sured at end diastole according to the American Society of
Echocardiography leading-edge convention (23,24). LVEDD
was used to calculate LV mass by a necropsy-validated for-
mula (25). Standard two-dimension volumetric methods were
used to calculate ejection fraction (EF; Teichholz formula).
Systolic (s¢), early (e¢) and late (a¢) diastolic mitral annulus
velocities were recorded by pulsed wave tissue Doppler im-
aging (TDI; sample volume located at the medial mitral an-
nulus) (26). Isovolumic relaxation time (IVRT) was measured
using continuous wave Doppler recordings as the interval
from the closure spike of the aortic valve to onset of mitral
flow. PW Doppler recordings of transmitral flow velocities
were obtained between the tips of the mitral valve leaflets in
the apical four-chamber view. Early (E) and late (A) diastolic
components were recorded (18,27).
Biochemical determinations
Blood samples were obtained at different times during the
day after six hours of fasting and refraining from smoking. All
serum samples were stored at - 80 until batch analysis.
Thyroid hormone function tests (TSH, free T3 [FT3], free
thyroxine [FT4], and total T3 [TT3]) and TPOAbs were de-
termined using immuno-electrochemiluminescence (Roche
reagents) on Cobas 411 (Roche Diagnostics GmbH, Man-
nheim, Germany). The intra- and interassay CV% were less
than 10% for all measurements. The time of the day (morning,
afternoon, early evening) did not influence free thyroid hor-
mone levels. However, TSH levels were higher when blood
was drawn in the afternoon or early evening (mean TSH levels
1.54, 1.67, 1.98 mU/L respectively; ANOVA p<0.001).
Statistical analysis
TSH, FT3, FT4, and TT3 were analyzed both as a continuous
variable and using quartiles (quartiles TSH women: 0.27–1.08,
1.09–1.54, 1.55–2.08, 2.09–4.2 mU/L; quartiles TSH men: 0.27–
1.03, 1.04–1.47, 1.48–1.99, 2.00–4.2 mU/L; quartiles FT3
women: <2.80, 2.81–3.00, 3.01–3.24, >3.24 pg/mL; quartiles
FT3 men: <3.12, 3.13–3.36, 3.37–3.58, >3.59 pg/mL; quartiles
FT4 women: <1.15, 1.16–1.25, 1.26–1.35, >1.36 ng/dL; quar-
tiles FT4 men: <1.23, 1.24–1.34, 1.35–1.45, >1.46 ng/dL, quar-
tiles TT3 women: <104.5, 105–119, 119.5–139, >140 ng/dL;
quartiles TT3 men: <106, 106.5–117, 118–128, >129 ng/dL). All
statistical analyses (linear regression analysis and one-way
ANOVA) were performed using SPSS version 19 (SPSS Inc.,
Chicago, IL). Since men and women were analyzed together
to increase the power, analyses were first adjusted for sex.
Additional adjustment for age, height, weight, and current
smoking was performed in model 1. In a second model, we
further adjusted for heart rate and systolic blood pressure,
except for LV structure where adjustment for heart rate and
systolic blood pressure was done sequentially (model 2). For
diastolic function, we additionally adjusted for LVEDD and
relative wall thickness (model 3). We also checked for interac-
tions between thyroid hormones and heart rate. Statistical
significance was assumed for p-values less than 0.05. Data are
given as mean– SD for normally distributed data or median
(interquartile range) for skewed data, unless noted otherwise.
Results
Descriptives
Descriptives for the general characteristics, TSH and thy-
roid hormone levels, and echocardiographic measures of LV
function and structure are shown in Table 1. Subjects on
thyroid hormone substitution, antithyroid drugs, or anti-
hypertensive medication, and with TPOAbs above clinical
cut-off or with TSH levels outside the reference range were
excluded from the present analysis, as stated in the methods
section, leaving 2078 subjects (see Fig. 1).
Men have higher FT3 and FT4 levels ( p<0.0001), lower T3
levels ( p<0.0001), and slightly lower TSH levels (nonsignifi-
cant, p= 0.08) compared to women. In women, TT3 and FT3
were positively related to the use of oral contraceptive ther-
apy (b = 0.6, p <0.0001; b= 0.15, p <0.0001 respectively).
Mean heart rate levels were on average 4– 0.4 beats per
minute lower in men than women ( p <0.0001) and compara-
ble with mean heart-rate levels in the EPIC-Norfolk study
(28). Current smokers have higher levels of FT3 (mean dif-
ference 0.18 – 0.03; p <0.001), TT3 (mean difference 0.10 – 0.01,
p<0.001), and FT4 (mean difference 0.03 – 0.01; p = 0.006), but
no differences in TSH levels were detected. Therefore, smok-
ing status was taken into account in the adjustment.
Systolic blood pressure was positively associated with FT3
(b= 0.12, p<0.001), TT3 (b = 0.13, p<0.001), and TSH (b= 0.09,
p<0.001), but not with FT4 ( p= 0.8).
Associations between thyroid hormone status
and heart rate
In Figure 2, associations between quartiles of FT3, TT3, and
TSH and heart rate for subjects with TSH within the reference
range are shown. Mean heart rate increased significantly with
increasing quartiles of FT3 and T3, both in men and in women
(mean difference –five beats per minute; ANOVA p <0.0001).
When associations between circulating thyroid hormone
levels and heart rate were explored in a linear model, we
observed again a highly significant positive association be-
tween FT3 and heart rate, both in a model that only adjusted
for sex (b= 0.19, p<0.001) as in model 1 (adjusted for sex, age,
height, weight, and active smoking; b=0.17, p<0.001). This as-
sociation remained highly significant when analyses were
restricted to subjects within the narrow TSH range (model 1:
b= 0.16, p <0.001). Comparable associations were observed
between heart rate and TT3 concentrations: (b = 0.21, p<0.001)
in a model only adjusting for sex and (b= 0.18, p<0.001) and in
model 1 (adjusted for sex, age, height, weight, and active
smoking). Also, when restricting the analyses to subjects
within the narrow TSH range, the association with TT3
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remained highly significant (model 1: b = 0.18, p<0.001). No
significant associations were observed between heart rate and
TSH or FT4 levels.
Associations between thyroid hormones
and systolic function
Ejection fraction was not associated with free thyroid hor-
mone levels, TT3, or TSH. FT3 was positively associated with
the peak velocity of systolic annular motion s¢ (FT3: b = 0.06,
p = 0.01) and negatively with end-systolic diameter (LVESD;
b = - 0.05, p= 0.04) in a sex-adjusted model. However, these
associations became insignificant after additional adjustment
for age, height, weight, and smoking or when considering the
subgroup within the narrow TSH range. TT3 was also posi-
tively related to the peak velocity of systolic annular motion s¢
(TT3: b = 0.13, p <0.0001), and this association remained sig-
nificant after adjustment for age, height, weight, and smok-
ing, and when limiting analyses to subjects within the strict
TSH range. TT3 was not associated with LVESD or EF.
Associations between thyroid hormones
and diastolic function
In Table 2, associations between the main diastolic param-
eters derived from transmitral flow (E and A) and mitral an-
nulus motion (e¢ and a¢) and thyroid hormone levels and TSH
are shown. The most important finding was the positive as-
sociation between circulating thyroid hormones (FT4, TT3, and
FT3) and A and a¢, parameters of late ventricular filling (re-
flecting atrial contraction), in several adjusted models. Besides,
positive associations between TT3 levels and parameters of
Table 1. Descriptives for the Study Population
(n = 2078)
Variable Women (n = 1013) Men (n = 1065)
General characteristics
Age (years) 45 [40–50] 46 [41–51]
Height (cm) 163– 6 176 – 7
Weight (kg) 65.4 – 11.6 81.1 – 12.2
BMI (kg/m2) 24.5 – 4.2 26.2 – 3.6
Smoking
(active/ex/never; %)
19/21/60 22/36/42
TSH and thyroid hormones
TSH (mU/L) 1.54 [1.08–2.08] 1.47 [1.03–2.04]
FT4 (ng/dL) 1.25 [1.15–1.35] 1.34 [1.23–1.44]
FT3 (pg/mL) 3.0 [2.8–3.2] 3.4 [3.1–3.6]
TT3 (ng/dL) 120 [105–140] 118 [107–129]
Blood pressure and heart rate
Systolic BP (mm Hg) 121– 13 130 – 12
Diastolic BP (mm Hg) 77– 9 82 – 9
Heart rate
(average; bpm)
68– 9 64 – 10
Echocardiographic parameters
Systolic function
Ejection fraction (%) 67– 8 65 – 8
s¢ (mm/s) 80– 11 79 – 12
LVESD (mm) 28– 4 32 – 4
Diastolic function
E (cm/s) 79– 14 71 – 13
A (cm/s) 62– 11 59 – 10
e¢ (mm/s) 96– 21 87 – 18
a¢ (mm/s) 86– 15 92 – 15
LV structure
LV mass (g) 121– 29 177 – 39
LVMI (g/m2) 71– 14 90 – 18
LVEDD (mm) 45– 4 49 – 4
Relative wall thickness 0.36 – 0.06 0.39 – 0.07
Subjects on thyroid or antihypertensive medication, with anti-
thyroperoxidase antibodies above clinical cut-off, and with TSH
levels outside the reference range were excluded from further
analyses. Data are mean– SD or medians [first, third quartile] in case
of non-Gaussian distribution. Conversion factor for FT3 from pg/mL
to pmol/L and for TT3 from ng/dL to nmol/L is · 0.0154;
conversion factor for FT4 from ng/dL to pmol/L is · 12.87.
T3, triiodothyronine; TSH, thyrotropin; FT4, free thyroxine; FT3,
free T3; TT3, total T3; LVESD, left ventricular end-systolic diameter;
s¢, systolic mitral annulus velocity; E, early diastolic transmitral flow
velocity; A, late diastolic transmitral flow velocity; e¢, pulsed-wave
tissue Doppler early diastolic component; a¢, pulsed-wave tissue
Doppler late diastolic component; LVMI, left ventricular mass index;
LVEDD, left ventricular end-diastolic diameter.
FIG. 2. Mean heart rate according to quartiles of FT3, TT3,
and TSH (within reference range for TSH). A higher quartile
of FT3 is associated with a gradual increase in heart rate; a
higher quartile of TSH is not. p-Values result from analysis of
variance (overall difference between categories). Error bars
represent standard error of the mean. T3, triiodothyronine;
FT3, free T3; TT3, total T3.
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early ventricular filling were observed. In contrast, we did not
observe these associations for free thyroid hormones. Interest-
ingly, TSH was inversely related to early diastolic myocardial
relaxation as evaluated by e¢. Reported associations between
FT3, FT4, and TT3 and parameters of diastolic function re-
mained significant when limiting analyses to subjects within
narrow TSH levels (data not shown). The associations between
FT4 and late ventricular filling and the associations between
TT3 and early ventricular filling appeared to be independent
from the effects of thyroid hormone on heart rate or systolic
blood pressure. A negative association was further observed
between IVRT and FT3 (b= - 0.06, p= 0.007) and TT3 (b= -
0.10, p<0.0001) in a sex-adjusted model and for TT3 also in
models 1–3. However, for FT3 or other thyroid parameters, no
associations with IVRT were observed after further adjustment
in models 1–3 (data not shown).
Associations between thyroid hormones
and LV structure
Associations between free thyroid hormones, TT3, and
TSH and two parameters of left ventricular structure (LVEDD
Table 2. Associations Between TSH and Thyroid Hormone Concentrations
and Parameters of Diastolic Left Ventricular Function
E (mm/s) A (mm/s) e¢ (mm/s) a¢ (mm/s)
b p b p b p b p
TSH (mU/L)
Sex-adjusted - 0.02 0.5 0.007 0.8 - 0.05 0.01 0.008 0.7
Model 1 - 0.02 0.4 0.001 0.9 - 0.05 0.006 - 0.001 0.9
Model 2 - 0.02 0.3 - 0.02 0.2 - 0.04 0.03 - 0.02 0.4
Model 3 - 0.03 0.2 - 0.02 0.2 - 0.05 0.009 - 0.02 0.4
FT4 (ng/dL)
Sex-adjusted - 0.02 0.4 0.005 0.8 0.04 0.06 0.03 0.2
Model 1 - 0.04 0.06 0.05 0.01 - 0.008 0.6 0.07 0.002
Model 2 - 0.03 0.1 0.04 0.03 - 0.006 0.8 0.06 0.004
Model 3 - 0.04 0.09 0.04 0.03 - 0.01 0.6 0.06 0.005
FT3 (pg/mL)
Sex-adjusted 0.02 0.4 0.06 0.01 0.02 0.5 0.05 0.05
Model 1 - 0.03 0.2 0.08 <0.0001 - 0.04 0.06 0.08 <0.0001
Model 2 - 0.02 0.5 0.01 0.6 - 0.02 0.4 0.02 0.4
Model 3 - 0.01 0.5 0.009 0.7 - 0.2 0.4 0.02 0.4
TT3 (ng/dL)
Sex-adjusted 0.07 <0.0001 0.11 <0.0001 0.06 0.009 0.05 0.02
Model 1 0.04 0.04 0.10 <0.0001 0.04 0.03 0.06 0.007
Model 2 0.07 0.001 0.02 0.2 0.07 <0.0001 0.007 0.7
Model 3 0.07 0.001 0.02 0.2 0.06 0.001 0.008 0.7
Results from linear regression analysis according to several models: a sex-adjusted model; a model with additional adjustment for age,
height, weight, and active smoking; a model with additional adjustment for systolic blood pressure and heart rate; and a model with
additional adjustment for LVEDD and relative wall thickness. Parameters of diastolic function (E, A, e¢, and a¢) were used as dependent
variables; TSH, FT4, FT3 and TT3 were independent variables.
Table 3. Associations Between TSH and Thyroid Hormones and Parameters of Left Ventricular Structure
TSH (mU/L) FT4 (ng/dL) FT3 (pg/mL) TT3 (ng/dL)
b p b p b p b p
LVEDD (mm)
Sex-adjusted - 0.01 0.5 - 0.05 0.015 - 0.04 0.046 - 0.04 0.05
+ Adjustment for age, height,
weight, and smoking
- 0.02 0.4 - 0.03 0.2 - 0.05 0.009 - 0.06 0.002
+ Adjustment for systolic
blood pressure
- 0.02 0.3 - 0.03 0.2 - 0.06 0.005 - 0.06 0.001
Relative wall thickness
Sex-adjusted 0.01 0.5 - 0.02 0.4 0.07 0.006 0.06 0.005
+ Adjustment for age, height,
weight, and smoking
0.01 0.6 0.01 0.6 0.06 0.007 0.04 0.09
+ Adjustment for systolic
blood pressure
- 0.002 0.9 0.01 0.6 0.04 0.06 0.02 0.5
Results from linear regression analysis according to several models: a sex-adjusted model; a model with additional adjustment for age,
height, weight, and active smoking; and a model with additional adjustment for systolic blood pressure. Parameters of LV structure (LVEDD
and relative wall thickness) were used as dependent variables; TSH, FT4, FT3, and TT3 were independent variables.
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and relative wall thickness) are shown in Table 3. Free and
total T3 were negatively associated with LVEDD and posi-
tively associated with relative wall thickness in several
models. Associations with relative wall thickness disappeared
after adjustment for blood pressure.
Discussion
In the present study, we investigated whether between-
subjects variation in thyroid hormone levels within the ref-
erence range affects heart rate, cardiac structure, and function
in a population-based sample of apparently healthy middle-
aged euthyroid men and women. Our study shows a gradual
and robust positive association between FT3 levels and heart
rate, even in a strictly defined euthyroid population. At a
structural level, the data suggest a decreasing cavity size
(LVEDD) with increased relative wall thicknesses with higher
circulating thyroid hormones. Although no associations are
found with EF, TT3 is associated with enhanced LV systolic
function (as assessed by more sensitive tissue Doppler imag-
ing, s¢). With regard to diastolic function, higher (free) thyroid
hormone levels are related to higher A and a¢ and higher TT3
levels to higher E and e¢. These data suggest an enhanced
atrial contraction (mirroring the effects in the LV) and en-
hanced LV relaxation with higher thyroid hormone levels.
This study is the first to explore associations between thy-
roid hormone levels and heart rate, cardiac function, and
structure in a large, carefully selected group of healthy, non-
hypertensive euthyroid middle-aged subjects. The strengths
of this study are the extensive cardiac characterization of a
rather large population, together with the determination of
TSH as well as circulating free thyroid hormones, the last
being in contrast with a previous study, performed in the
Framingham cohort (11). As methodological issues in the
determination of FT3, for example due to changes in binding
proteins or analytical problems, have been described, total
T3 levels were also determined. Furthermore, a (strictly) eu-
thyroid population was selected, excluding subjects with
thyroid medication, positive TPO antibodies, or TSH levels
outside the (strict) reference range. Finally, we studied a
population without clinically overt presence of atherosclero-
sis and excluded subjects with drug-treated hypertension
from our analyses, contrary to the recently published study of
Iida et al. (17).
We have shown positive associations between heart rate
and FT3. Sinus tachycardia and decreased heart rate vari-
ability are the most common cardiovascular signs of (SC)
hyperthyroidism (29–32). Also, a positive association between
FT3 and heart rate in thyroid hormone resistance was ob-
served (30). This is in accordance with the known positive
chronotropic effect of T3 through binding to TRa, the pre-
dominant thyroid receptor in myocardial tissue (2,33), but we
are the first to prove this effect within a strictly euthyroid
range.
Extending our observation of a positive association be-
tween FT3 and heart rate, we investigated whether circulating
thyroid hormone levels within the reference range were as-
sociated with cardiac function as well, and whether these
associations were heart rate–dependent. In hyperthyroid pa-
tients, there is a consistent increase of LV systolic function at
rest (2–4). Indeed, we found a positive association between
TT3 levels and s¢, a sensitive parameter of systolic function.
Diastolic dysfunction is reported both in (SC) hypothy-
roidism (8,9,33) as well as in SC hyperthyroidism (14,15).
Nevertheless, theoretically, T3 exerts a beneficial effect on
diastolic function. Two opposing effects can govern this as-
sociation. First, T3 improves myocardial relaxation by affect-
ing the sarcoplasmic reticulum proteins, calcium-activated
ATP-ase, and phospolamban (34). Second, a higher heart rate
( >90 beats per minute) counteracts this improvement of di-
astolic function by reducing total diastolic filling time, and
thus leads to a greater dependence on atrial systole (33).
Moreover, in longstanding SC hyperthyroidism, this potential
favorable effect on diastolic function can be counteracted by
the concomitant ventricular hypertrophy induced by the
chronically increased cardiac workload (29). As both thyroid
hormone deficit as well as excess have been associated with
diastolic dysfunction, interpretation of our data is difficult.
However, the data are suggestive of a positive contractile ef-
fect at the atrial level (positive effects on A and a¢), and pos-
sibly an enhanced ventricular relaxation (as TSH was
inversely and TT3 positively related to early diastolic myo-
cardial relaxation, evaluated by e¢ and E) with higher thyroid
hormone levels.
Finally, thyroid hormone status can affect LV structure. In
longstanding hyperthyroidism, a compensated concentric
cardiac hypertrophy occurs, caused by an increased protein
synthesis in cardiac myocytes (1). However, changes in heart
structure are also possible in SC thyroid disease. A modestly
higher LV mass was reported in SC hypothyroidism (8,9).
Long-term SC hyperthyroidism consequent to levothyroxine
treatment can lead to a higher LV mass as well (14,29), yet this
higher LV mass has not been observed in all studies on en-
dogenous SC hyperthyroidism (10–13), due to varying dura-
tion of thyroid hormone excess. Only one other study on the
effects of thyroid hormone status within the reference range
on LV mass exists. Iida et al. (17) have very recently reported
on linear relationships between peripheral thyroid hormones
(positive) and TSH levels (negative) within the reference
range and LVMI in a hypertensive population. Besides, TSH
and FT3 levels were associated with changes in LV geometric
pattern. (17). In our study, which excluded subjects with
drug-treated hypertension, we still observed associations be-
tween thyroid hormones and LV structure. A negative asso-
ciation between FT3 and LVEDD together with a positive
association between FT3 and relative wall thickness were
observed in our study, suggesting a fine balance between
higher wall thicknesses but smaller cavity size (LVEDD) with
higher circulating FT3 levels. These findings seem to fit within
the known framework of findings in more disturbed thyroid
function. Both hyper- and hypothyroidism could thus lead to
hypertrophy; the former through wall thickening (once the
diminution of LVEDD would plateau quite quickly), the latter
through chamber enlargement (the main driver of LV mass).
These findings suggest that optimal cardiac effects of circu-
lating thyroid hormones operate within very tight, counter-
balancing boundaries, with both hypo- and hyperfunction
leading to hypertrophy.
Noteworthy are our observations of sex differences in heart
rate and thyroid function tests. We observed a small but sig-
nificant sex difference in mean heart rate of four beats per
minute, with men having lower heart rates than women.
Previous studies on this topic, both older and more recent
studies, showed almost the same trend; namely, slightly lower
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mean heart rates in men compared to women (difference be-
tween three and six beats per minute) (28,35–39). Regarding
the sex differences in thyroid function tests, we observed
higher FT3 and FT4 levels, and slightly lower TSH and TT3
levels in men than in women. Studies on sex differences in
thyroid hormone levels are scarce, and results are conflicting
(40–42), possibly because observations result from cohorts
with diverging age ranges. However, our results in middle-
aged subjects are in agreement with observations from Gullo
et al. (43) and Kratzsch et al. (44).
Several limitations should be acknowledged. First, this is a
cross-sectional study, so no causal inferences can be made.
Second, heart rate was not recorded by 24-hour Holter electro-
cardiography but was averaged from eight different record-
ings throughout the examination, establishing an averaged
heart rate over a one-hour period. Finally, blood samples
were taken at different times of the day. This might have led
to significant variation in TSH levels, acknowledging that
the diurnal variation in TSH concentrations approxima-
tes 50% (45). The time of blood sampling indeed had
an influence on TSH levels but not on FT3, T3, and FT4
concentrations. Therefore, it is unlikely that time of the day
influenced the observed associations with free thyroid
hormones.
In conclusion, in a well-defined general population sample,
excluding clinical thyroid disease, confounding antihyper-
tensive treatment and elevated anti-TPO levels, we have
demonstrated a highly significant association of between-
subject variation in FT3 and T3 levels within the euthyroid
range and heart rate. Also, we observed more discrete effects
on systolic and diastolic function and on LV structure. More
specifically, the data suggest a smaller LV cavity size (with
increased relative wall thickness), an enhanced atrial and
ventricular contraction, and an enhanced LV relaxation with
higher circulating thyroid hormones. This illustrates that
variation of thyroid hormone levels, even within a very strict
euthyroid range, exerts effects on the heart. However, the
degree of CV functional changes seen across the ‘‘euthyroid’’
thyroid function test spectrum all remain within the bound-
aries of ‘‘normal function’’ and thus cannot automatically be
proposed to have predictable clinical significance.
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